Ritonavir
- Generic Name
- Ritonavir
- Brand Names
- Kaletra, Norvir, Paxlovid, Viekira Pak, Ritonavir Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C37H48N6O5S2
- CAS Number
- 155213-67-5
- Unique Ingredient Identifier
- O3J8G9O825
- Background
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibi...
- Indication
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
...
- Associated Conditions
- Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 1b, Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection
- Conditions
- First Posted Date
- 2004-12-01
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00097799
- Locations
- 🇺🇸
1182.70.066, Los Angeles, California, United States
🇺🇸1182.70.174, Macon, Georgia, United States
🇺🇸1182.70.071, Los Angeles, California, United States
Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults
- Conditions
- Interventions
- First Posted Date
- 2004-11-17
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 18
- Registration Number
- NCT00096850
- Locations
- 🇺🇸
Vanderbilt Therapeutics CRS, Nashville, Tennessee, United States
🇺🇸The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
🇺🇸Stanford CRS, Palo Alto, California, United States
48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection
- Conditions
- Interventions
- First Posted Date
- 2004-08-10
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 110
- Registration Number
- NCT00089583
- Locations
- 🇪🇸
GSK Investigational Site, Vigo ( Pontevedra), Spain
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
- Conditions
- First Posted Date
- 2004-06-21
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 866
- Registration Number
- NCT00085943
- Locations
- 🇨🇭
GSK Investigational Site, St Gallen, Switzerland
Atazanavir/Ritonavir Maintenance Therapy
- Conditions
- First Posted Date
- 2004-06-07
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 36
- Registration Number
- NCT00084019
- Locations
- 🇺🇸
University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States
🇺🇸Dallas VAMC, Dallas, Texas, United States
🇺🇸University of Colorado Hospital CRS, Aurora, Colorado, United States
Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
- Conditions
- Interventions
- First Posted Date
- 2003-10-31
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 59
- Registration Number
- NCT00071760
- Locations
- 🇿🇦
GSK Investigational Site, Soweto, South Africa
Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2003-07-11
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 33
- Registration Number
- NCT00003008
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men
- First Posted Date
- 2003-07-08
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 44
- Registration Number
- NCT00063804
- Locations
- 🇺🇸
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸University of Washington AIDS CRS, Seattle, Washington, United States
Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
- Conditions
- First Posted Date
- 2003-03-21
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 328
- Registration Number
- NCT00056641
- Locations
- 🇺🇸
UT Southwestern, Dallas, Texas, United States
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
🇩🇪Boehringer Ingelheim Investigational Site, Stuttgart, Germany
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults
- Conditions
- Interventions
- First Posted Date
- 2003-01-20
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 19
- Registration Number
- NCT00051831
- Locations
- 🇺🇸
University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States
🇺🇸Washington U CRS, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.